Uracil-5-Boronic Acid: A Closer Look from the Manufacturer's Bench

Introduction to a Key Boronic Acid Building Block

From our experience in developing and scaling up nucleobase derivatives, Uracil-5-Boronic Acid stands out for its cross-coupling utility and straightforward handling in synthesis labs focused on nucleoside, nucleotide, and drug intermediate research. Chemists requiring boronate species with reliable batch-to-batch consistency soon notice what a difference it makes sourcing from a genuine producer. We see the value of delivering a product that's not just pure on paper but lives up to its promise every single time it is used under palladium-catalyzed or Suzuki–Miyaura conditions.

Details That Matter: Molecular Characteristics and Presentation

Our Uracil-5-Boronic Acid (CAS 815667-78-4, C4H5BN2O4) comes in white to off-white powder form. Most chemists request material with a purity of no less than 98%, based on HPLC traceable to authentic standards. Appearance and purity aren’t where the attention to detail ends, either. Moisture content, heavy metal traces, and residual solvents always spark questions from synthetic chemists. We ship product sealed, inside double PE bags, inside light-proof containers. While working with this compound in Suzuki couplings, our own project teams have noted reduced side reactions thanks to consistently low residual water, below 1% as measured by Karl Fischer titration.

Applications: From Nucleic Acid Chemistry to Medicinal Lead Discovery

Demand for high-purity boronic acids like uracil-5-boronic acid has climbed in the past decade, with nucleoside analogues renewing interest across both antiviral and cancer therapy research. Chemists focus on the 5-position functionalization of uracil precisely because that spot can tolerate bioisosteric substitutions without disrupting base-pairing properties—in other words, you still get recognizably ‘uracil-like’ hydrogen bonding but now with unique flexibility for introducing substituents through Suzuki reactions. Several research groups have built pyrimidine-based kinase inhibitors or antiviral scaffolds using this exact intermediate. Producing and qualifying such building blocks in-house, we routinely participate in collaborations that push these modifications beyond the literature—sometimes running new coupling reactions ourselves to verify discussions with partner labs.

Handling Practicalities in Real-World Chemistry

Lab feedback comes in handy when addressing day-to-day obstacles chemists face. We formulate our uracil-5-boronic acid to enable direct weighing on the bench—grain size is kept fine enough to avoid static cling but not so fine that the powder flies. Once unsealed, material should be handled under dry air or nitrogen; any clumping signals re-absorption of atmospheric moisture, hampering precise dosing in micro-mole scale syntheses. Some customers asked for lower packaging weights, allowing them to minimize waste in sensitive fragment-based drug work. After investigating our batch stability, we responded by offering 100 mg vials, as well as the more standard 1 g and 5 g options suitable for parallel library synthesis.

Reliability in Sourcing: Lessons Learned from Downstream Failures

Too many medicinal chemistry groups end up with sub-par nucleoside intermediates due to unknown impurities in their building blocks. The boronic acid functionality in particular gives rise to side pathways—think undesired protodeboronation or boronic anhydride formation—if pH, storage, or packaging are neglected. Years spent running our own scale-ups and building process analytical controls made this risk obvious. To that end, every release is supported not just by purity and NMR/LCMS proof, but also impurity profiling, trace metal data, and drying logs. We found out the hard way that poorly controlled boron sources waste more time than they save in terms of the headline price.

Understanding What Sets Our Uracil-5-Boronic Acid Apart

Direct conversation with researchers guides much of what we do. Early on, we learned that simple benchmarks like “it’s the same as the other boronic acid, just with uracil” did not hold up. Yields, product workup, and shelf stability all swing depending on how strictly the initial boronic acid is manufactured and purified. In contrast to generic material in the market, our process tolerates neither boroxine contamination nor carryover organic solvents from chromatography. Each synthesis run involves continuous moisture monitoring and solvent removal staged to avoid thermal decomposition of the uracil ring. As a result, downstream coupling reactions stay repeatable in both academic and industrial settings.

Supporting Data and Real-Use Feedback

Scientists in the field keep sharing their experiences with us. Some have reported spotting red/brown discolorations in competing materials, sometimes indicating boroxine ring formation—products that don’t perform predictably in the Suzuki coupling step. Our process gives colorless to faint cream powder, with every lot cross-checked by NMR and by test-coupling on 2-iodohenyl derivatives under both aqueous and anhydrous conditions. LCMS baseline purity always exceeds 98%. Notably, Dr. Aikawa’s group at Kyoto used our material to synthesize uracil-modified probe analogs, confirming solid reproducibility between batches. We use their feedback to tweak our post-synthesis drying and final sieving protocols.

Comparisons to Related Building Blocks

As a nucleobase boronic acid, the uracil-5-boronic acid fills an important niche. Compare it, for instance, with phenylboronic acid or pyridine boronic acid derivatives: uracil-5-boronic acid presents a hydrogen bonding face more amenable to biologically-relevant interactions. Unlike the generic aryl boronic acids, which easily crystallize and sometimes cause plugging issues in automated assemblies, uracil-5-boronic acid’s morphology leans toward freely pourable microcrystalline powder. Purity control must focus on boroxine and triol formation, usually less of an issue for alkyl or aryl boronic acids. And unlike 2-aminopyridine boronic derivatives, the uracil core offers distinctly lower basicity, which avoids numerous workup headaches in biological buffer systems.

Aside from structural differences, use cases also diverge. Most aryl and alkyl boronic acids remain in demand for polymer or sensor chemistry; nucleobase boronic acids tend to go into higher-value projects such as drug leads or nucleic acid probe construction. Every shipment of our uracil-5-boronic acid caters to these higher standards, including rigid light- and moisture-exclusion protocols in our facility.

Solubility and Reaction Performance from Bench to Scale

Uracil-5-boronic acid dissolves selectively in polar aprotic solvents like DMF and DMSO, matching the conditions chemists prefer for cross-coupling. During small-scale validation, we use NMP as a co-solvent and find little byproduct formation on warming (under 80°C) with alkyl halides and aryl bromides. Users should expect nearly quantitative conversion to boronate complexes where catalysts and bases align to expected Suzuki-Miyaura protocols. We’ve scaled reactions to >100 mmol in-house, confirming that no unusual exotherms or decomposition occurs under standard reaction setups. In contrast, analogs such as guanine boronic acid prove much trickier, often suffering lower solubility and greater tendency to hydrolyze.

Long-Term Stability: More than a Shelf-Life Number

Our own chemists have a healthy skepticism toward quoted shelf-lives. Even the ideal storage of boronic acids loses meaning if the initial product is barely stable from the start. We have retained reference samples for over three years, finding only minimal loss in reactivity or changes in NMR signatures. Maintaining this stability requires light-proof, airtight packaging and regular stability studies. Recognizing that typical research group fridges fluctuate in temperature and humidity, we guide customers toward optimal storage routines to match what works in our own vaults. A batch shipped in January 2022 came back for retesting last year—no drop in coupling efficiency or shifts in the chromatographic profile.

Manufacturing Insights: From Small Batch to Bulk

Our focus remains on mid-scale organic synthesis, supporting both gram-quantity discovery work and several kilogram campaigns for preclinical materials. Each batch emerges from a solution-phase borylation on uracil, followed by isolation and purification designed expressly for functional group tolerance. The facility runs specialized drying and anti-static sieving to prevent losses and cross-contamination from other nucleobase boronic acids handled in parallel. What matters to us is that the output stays reproducible, both in terms of chemical purity and physical handling properties. The staff pride themselves on validating every step not only with instrument readouts, but also bench-level checks like solubility and color.

Collaborative Development Driven by Research Needs

We increase our batch output and process rigor due to the constant demands of fragment-based lead optimization and rapid analog screening. Synthesis requests often reach us with feedback from previous project failures: polymerization, side-product accumulation, or unexplained reaction delays. Our staff runs test couplings using actual customer ligands with each production lot. This extra step leads to a much tighter feedback loop, allowing optimization not just in purity routines but in isolation, micronization, and even solvent switching protocols.

Purity, Traceability, and Analytical Transparency

Pure numbers on a certificate never tell the whole story—our facility values onsite NMR and LC-MS checks far more than paperwork. Every batch of uracil-5-boronic acid carries internal lot traceability, with backup aliquots archived for reference. This practice began after a failed campaign in 2015, where the market required us to re-investigate an unexplained drop in cross-coupling yields linked to a contaminated aryl boronic acid. That episode taught us that traceability and long-term storage of reference samples respond better to troubleshooting than any number of repeated elemental analyses.

Shortcomings, Solutions, and What We Keep Improving

There’s always a learning curve in handling nucleobase boronic acids. Static buildup, powder bridging, and accidental hydrolysis each cropped up as issues in early internal campaigns. We invested in anti-static packaging and climate-control hoppers in response. For customers working in high-throughput setups, we added lot-by-lot advice on handling, minimizing sample loss. Some downstream users asked for pre-measured, press-sealed aliquots to avoid introducing water from open bench conditions; we pioneered these for our uracil-5-boronic acid, shipping microtubes alongside sealed vials, giving users just enough for a single synthesis while ensuring quality from start to finish.

Production teams participate directly in scale-up troubleshooting when library syntheses lag behind. We routinely run pilot reactions to uncover batch-specific variations. By incorporating both direct spectroscopic monitoring and parallel small-scale cross-coupling tests, we spot lot-to-lot deviations faster than relying on external analytics alone. A major lesson: practical reactivity always trumps theoretical certificate numbers.

Safety and Regulatory Mindset Built on Real Life Use

Compared to some boronic acids carrying acute toxicity concerns, uracil-5-boronic acid rarely raises red flag issues in our own hazard assessments. Still, standard PPE—gloves, goggles, appropriate ventilation—remains mandatory throughout synthesis, packing, and even lab usage, especially during weighing and sample transfer. Handling powders comes with challenges: fine aerosol particles, electrostatic buildup, inadvertent skin contact. By minimizing batchwise dust through careful sieving and humidity control, our teams experience fewer handling interruptions. Ongoing reviews push us to monitor for potential new hazard data, recognizing that regulatory standards may evolve quickly, especially for new therapeutic applications.

Championing Quality in a Crowded Market

The explosion in building block suppliers has flooded the market with variable-grade uracil-5-boronic acid, some of it synthetic off-cuts diverted from unrelated projects. End users run a real risk of buying contaminated, mischaracterized, or substandard intermediates—burning months on failed scale-ups or troubleshooting. Our position as actual producers means we control every stage: reactant sourcing, in-process analytics, final QC, and post-sale support. Feedback ties directly to staff in the facility, which means process tweaks happen on a real-world timeline, not dragged out for a quarterly review. We do not subcontract critical steps like drying, analytical validation, or packaging, and this hands-on involvement proves vital when troubleshooting or running new reaction screens.

Environmental Responsibility in Laboratory-Scale Production

Chemical manufacturers walk a tightrope between maintaining rigorous quality and minimizing environmental impact. Our teams design and operate containment and recovery systems to minimize organic solvent emissions and energy use during production. Waste boron stream management remains a priority, and efforts focus on recycling and safe disposal in compliance with evolving guidelines. Each step balances on-the-ground practicality—using solvents with lower toxicity, choosing drying techniques that reduce fugitive emissions, and transparently reporting process wastes. Our customers are increasingly aware of sustainability concerns—and ask for details about the solvents, reagents, and energy inputs that go into each gram of finished uracil-5-boronic acid. We continue to tune our processes accordingly.

Experience Drives Industrial Progress

Refining uracil-5-boronic acid manufacturing is not just about chemistry, but about a culture of continuous improvement—and about taking direct feedback from the benches of research labs around the globe. Each batch owes its performance not just to a list of specifications on a product sheet, but to the lessons learned through repeated hands-on syntheses, problem-solving, and open communication with chemists who demand reliable results. We see our role as more than a supplier: we are partners in the scientific work that advances nucleoside analog chemistry, medicinal chemistry, and beyond. The close loop between production and application ensures each lot carries with it both technical excellence and practical reliability, grounded in experience and a real commitment to scientific progress.